Background: The field of pediatric palliative oncology is newly emerging. Little is known about the characteristics and illness experiences of children with cancer who receive palliative care (PC).
INTRODUCTION
Cancer is the leading cause of death by disease among children in the United States. Approximately one in 285 children is diagnosed with cancer each year, and despite advances in therapy, currently one in five children with cancer does not survive his/her illness. 1 Children with high-risk cancer and their families face significant physical, psychological, social, and spiritual challenges, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and they require Abbreviations: EOL, end of life; PC, palliative care; PICU, pediatric intensive care unit; PPO, pediatric palliative oncology; QOL, quality of life expert guidance in navigating difficult decision making and reframing hope in the face of unspeakable tragedy. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Over the past decade, the field of palliative oncology has developed, 26, 27 bolstered by evidence that patients with high-risk or incurable disease who receive cancer-directed care in synergy with palliative care (PC) demonstrate improved outcomes. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Specifically in the context of pediatric cancer, the value of palliative oncology has gained traction over the past few years. [38] [39] [40] [41] [42] Integration of PC principles and services into routine cancer care for children with high-risk disease has been associated with improved symptom management for patients 5 , 43 and quality of life (QOL) for both children and families. [44] [45] [46] [47] The advent of combined training programs in pediatric oncology and hospice and palliative medicine further aims to improve delivery of care for this unique patient population. 48 As pediatric palliative oncology (PPO) develops as a field, the patients and families it serves have emerged as a distinct cohort within the pediatric patient population. Yet little is known about the characteristics, illness trajectories, and end-of-life (EOL) experiences of children with high-risk or incurable cancer who receive PC services. Even less is known about how EOL experiences are associated with timing of PC consultation for pediatric oncology patients.
To address these deficits, we conducted a retrospective cohort study of deceased children with cancer enrolled on a PC service at a large academic pediatric cancer center over a 4-year period. This work builds upon a very limited literature describing pediatric PC cohorts, of which a small subset are oncology patients, 49 as well as recent cohort analyses of pediatric, adolescent, and young adult cancer patients, of which a subset received PC 5, 50 and a single study investigating goals of care and location of death for PPO patients. 51 To date, the literature is sparse on this topic in part due to limited numbers of PPO patients available for investigation; this analysis aims to address this deficit by presenting data from a large cohort of 321 patients. To our knowledge, this is the first study to investigate the demographics, disease characteristics, treatments, interventions, symptom burden, and EOL experiences of a uniquely vulnerable population, with the goal of better understanding this distinct cohort of patients and identifying potential future targets for improving their illness and EOL experiences.
METHODS

Study design
This study was conducted at St. Jude Children's Research Hospital (SJCRH). The SJCRH Institutional Review Board reviewed the study and deemed it exempt in the context of retrospective analysis of a deceased cohort. Institutional data were mined to obtain a list of all patients with a primary cancer diagnosis who were enrolled on the PC service at SJCRH at the time of their death and whose death occurred between April 1, 2011 and March 31, 2015. This 4-year window was selected for two reasons: (1) institution-wide data became available in the electronic medical record beginning on April 1, 2011, allowing for more thorough and accurate data abstraction; and (2) the characteristics of patients on the PC service and the frequency of requested PC consultations remained stable during this time period.
Upon careful review of available data, the decision was made to limit the cohort to patients with cancer who received PC as evidenced by documentation of at least one note in the medical record confirming PC or hospice involvement. This decision was predicated on the fact that 93.0% of patients who died during the study window had some degree of PC integrated into their care by the date of death; most of the small minority of patients who died without PC involvement were not followed at this institution at the time of death, resulting in limited availability of medical records. For the purpose of this investigation, deceased PPO patients served as an approximate surrogate for all patients with cancer who died during the 4-year study window. Given the very small number of patients who died without PC involvement at this institution, it was not statistically feasible to draw meaningful comparisons between patients who died with and without PC involvement.
Of note, for the target study population, provision of PC encom- Table 1. A team of six researchers (E.K., S.D., C.G., J.J., L.P., and L.J.) independently abstracted data from the electronic medical record using a standardized form. The two researchers who created the form (E.K. and D.G.) provided training to the remaining research team. For certain items, secondary review of paper charts was performed to supplement electronic medical record review. Any questions raised by a team member were discussed in groups of two to four researchers to clarify the abstraction tool and achieve consensus.
Auditing process
Three independent researchers (E.K., D.G., and L.P.) conducted a 10% audit of the entire database. Random sampling was performed to obtain a subset of cases for auditing. For database items relevant to all 321 patients, sampling of every tenth patient was performed. For items relevant only to select subsets of patients, random sampling was altered accordingly to ensure capture of 10% of the subset for auditing. An acceptable threshold for interrater reliability was established a priori at 0.85. All database items met this threshold; however, two items had interrater reliability scores at the lower limit of 0.85. Excluding the cases screened in the prior audit, a subsequent 15% audit was performed on these items, establishing interrater reliability scores of 0.90 for these data.
Statistical analysis
Demographic, disease, treatment, EOL, and QOL-related characteristics of PPO patients were summarized using descriptive statistics Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). A two-sided significance level of P < 0.05 was used for all statistical tests.
RESULTS
Description of the PPO patient population
A total of 321 St. Jude PPO patients died between April 2011 and March 2015. Demographic characteristics of these patients are summarized in Table 2 .
The disease and treatment history of the 321 PPO patients is summarized in Table 3 . Approximately one-fourth of patients had leukemia or lymphoma as their primary cancer diagnosis (24.0%), one-third had 
TA B L E 2 Demographics of pediatric palliative oncology (PPO) patients
Association between timing of PC involvement before death and location of death
The results of the multinomial logistic regression model exploring the relationship between days from first PC consult to death and location of death are shown in Table 6 . Patients with PC involvement occurring less than 30 days before death had a higher odds of dying the in the PICU over the home/hospice setting compared to those with PC involvement occurring 30 days or more before death (OR: 4.7, 95% CI:
2.47-8.97, P < 0.0001).
DISCUSSION
Cancer is the leading cause of death by disease among children in the although little is known about the extent of suffering experienced by PPO patients, these findings raise concerns about the potentially high levels of physical and psychosocial suffering sustained by children with cancer prior to death.
In particular, the extent of PICU burden on this patient population warrants closer attention. Prior literature suggests that one of every three to four children with cancer is hospitalized in the PICU during their illness, 56, 68 and PICU mortality for pediatric oncology patients TA B L E 6 Multinomial logistic regression modeling of the association between days from first PC consult to death and location of death has been shown to be fourfold higher than overall PICU mortality. 57, 58 However, this study suggests that the risk of PICU hospitalization may be increased even further in PPO patients. This finding is unsurprising to the extent that children with progressive disease often receive extensive therapy and experience significant illness-and treatmentrelated complications. 5 Importantly, these data further demonstrate that PC can and does overlap with intensive cancer-directed therapy.
Yet for the authors of this study, the high burden of PICU hospitalization in a PPO cohort provokes important questions about the extent to which intensive care in PPO patients is cost-effective, goal-concordant, and/or precludes provision of QOL-related care. We believe that PICU hospitalization for PPO patients is neither inherently Of additional interest is the negligible percentage of PPO patients who died in a hospice facility, which stands in contrast to adult oncology patients who die in greater numbers in hospice facilities. 69 This finding likely speaks to a lack of hospice facilities with pediatric expertise in the United States. 70, 71 To date, only 14% of participating hospice agencies report having formal pediatric PC services with specialized staff, 71 and a number of educational, procedural, and sociocultural barriers further impede provision of community-based EOL care for children and families. 72 Development and implementation of interventions to improve access to pediatric PC and hospice in the community is a valuable area of research that remains largely unexplored. 73 Importantly, three-quarters of PPO patients at this institution had PC involvement prior to the LMOL, with the median time between initial consultation and death falling at approximately 2.5 months. These findings reflect a growing acceptance of PC in the context of pediatric oncology, bolstered by gradually increasing support for integration of PC into the care of children with cancer. 40, 74 Notably, at the time of initial PC consultation, nearly half of patients identified their goal of care to involve cure. These data highlight a growing awareness on the part of patients and families and clinicians that PC is not synonymous with EOL, 75 and they speak further to the importance and acceptability of early PC integration in pediatric cancer care. 40, 74, 75 Both of these points are important to emphasize, as they have the potential to ini- Despite the fact that nearly half of PPO patients and families identified cure-oriented goals at the time of initial PC consultation, the majority of PPO patients had advance directives in place at the time of death, with median documentation occurring more than 3 weeks prior to death. This finding is powerfully reflective of the journey to reframe hope in the context of goals of care, 76 and more research is needed to better understand how the extent and timing of PC involvement potentially impacts the gradual evolution of goals from cure to comfort.
These findings also demonstrate an important association between timing of PC consultation and location of death that deserves further exploration. Specifically, those PPO patients who first received PC services in the LMOL had higher odds of dying in the PICU. Although the nature of this finding is associative rather than causal, it highlights the need for prospective investigation of the impact of earlier PC involvement on goal-concordant care around location of death. Institutionspecific automatic PC consultation for select high-risk patient subpopulations is one potential strategy to facilitate earlier PC involvement, 41 and our center is currently investigating the feasibility and effect of "trigger-based" PC consults for all children who undergo hematopoietic stem cell transplantation. A significant barrier to this model centers on oncologist resistance to the concept of a "trigger," which intrinsically connotes a "forced" or "imposed" intervention 41, 77 ; at our institution, we have found it to be helpful to reframe the concept of a "trigger" as simply an "institutional standard of care" for a prioridentified high-risk subgroups. Automatic PC involvement in the context of PICU hospitalization has not been well described in the context of pediatric oncology, and we hope that these data may serve as a foundation upon which to begin a dialogue about the possible benefits of routine standardized PC integration for children with high-risk cancer and their families.
This study has a number of limitations. First, it represents the experience of a single large academic cancer center that treats patients from across the country and internationally, with a potential selection bias for higher risk patients and families seeking more aggressive therapies. However, we hypothesize that children with high-risk cancer enrolled on a PC service do not reflect the average pediatric oncology population, regardless of institution. Based on our single-center findings, we believe that this population is a uniquely vulnerable subcohort that faces significant challenges irrespective of the treating center, and we advocate for the development of multisite studies to investigate the illness and EOL experiences specific to PPO patients across the country and globally. Second, retrospective data abstraction relies on precise clinical documentation. Although incomplete or missing data were minimal in this study, we cannot be certain that missing data occurred randomly. Third, retrospective cohort design limits our ability to make conclusions about chronology or causality; rather, we have identified consequential associations that warrant further investigation through prospective study. Fourth, for the minority of patients who left the institution, it is not possible to parse out the influence of institutionprovided PC versus local care. For those patients who died outside of our catchment area, we rarely have access to documentation from local centers or hospices. In our experience, however, the vast majority of patients and families who opt to go home at the EOL (whether locally or to other regions) do so with advance directives in place, such that we would expect patients who die at home to have similar EOL trajectories with regard to the metrics that we queried (i.e., receipt of aggressive interventions, hospitalizations, advance directives, etc.), regardless of whether they were followed by our PC team or by a local hospice. Our PC team also provides close guidance via telephone to local hospices, so care recommendations are fairly standardized regardless of where the patient is located at the EOL. For the very small minority of PPO patients who go elsewhere to seek further cancer-directed therapy, however, we have limited information regarding their illness and EOL experiences, inhibiting examination of influences of institutional PC as compared to local cancer care.
CONCLUSIONS
Children with high-risk cancer who receive PC often experience a high burden of intensive treatments during the illness course and at EOL, and a substantial number of PPO patients die in the PICU setting. PC involvement occurring less than a month prior to death is associated with increased risk of dying in the PICU for PPO patients. Further prospective investigation is needed to better understand how early PC involvement in children with high-risk cancer impacts both goal concordance and cost-effectiveness of care in the context of QOL and EOL.
